CLINICAL_TRIALS
trial_result
· 2013-08-30
Clinical Trial Update: Study to Assess the Effect of 24 Weeks of Treatment With Vildagliptin in Patients With Type 2 Diabetes [Phase 4]
Summary
A Phase 4 trial evaluating 24 weeks of Vildagliptin in patients with Type 2 diabetes mellitus has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Type 2 Diabetes Mellitus | Phase 4 | Status: COMPLETED